These exciting new products will be available for license or
distribution, following regulatory clearance. Covalon's ColActive®
Plus Ag collagen wound dressing for treatment of chronic wounds and
diabetic foot ulcers has been marketed and sold in the United States
and elsewhere since 2005.

Now in its 25th year, Spring SAWC is the largest annual gathering of
wound care clinicians in the United States. The symposium provides an
opportunity for Covalon to showcase its new wound care products to more
than 2,000 physicians, podiatrists, nurses, therapists, and researchers
and over 200 leading wound care product manufacturers, wholesalers and
distributors are expected to attend the 2012 Spring SAWC meeting.

"Our team is extremely excited to present our newest advanced wound care
products at this year's Spring SAWC meeting," said Brian Pedlar,
Covalon's Chief Executive Officer. "We are looking forward to
introducing our new line-up of products to our growing domestic and
international distribution channels and to medical product companies
who are looking to license breakthrough new products."

To learn more about Covalon's products and services, please visit us at
booth 134 in the Georgia World Congress Center from April 19th to 22nd
or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at bpedlar@covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.